Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genmab A/S ADR (NQ: GMAB ) 26.83 -0.17 (-0.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 661,659 Open 26.67 Bid (Size) 26.67 (2) Ask (Size) 27.37 (1) Prev. Close 27.00 Today's Range 26.67 - 27.00 52wk Range 24.53 - 42.72 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News What 8 Analyst Ratings Have To Say About Genmab July 15, 2024 Via Benzinga Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. July 15, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. Via Chartmill Performance YTD -16.44% -16.44% 1 Month +4.07% +4.07% 3 Month -5.96% -5.96% 6 Month -7.96% -7.96% 1 Year -33.72% -33.72% More News Read More NASDAQ:GMAB, an undervalued stock with good fundamentals. July 01, 2024 Via Chartmill Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma June 28, 2024 From Genmab A/S Via Business Wire AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway June 27, 2024 Via Benzinga Exposures Product Safety 10 Analysts Assess Genmab: What You Need To Know June 20, 2024 Via Benzinga What 9 Analyst Ratings Have To Say About Genmab May 20, 2024 Via Benzinga NASDAQ:GMAB is showing good growth, while it is not too expensive. May 02, 2024 Via Chartmill EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) June 26, 2024 From Genmab A/S Via Business Wire 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 Via InvestorPlace Despite its growth, NASDAQ:GMAB remains within the realm of affordability. June 21, 2024 Via Chartmill 7 Stocks That Could Safely 10X by 2030 June 06, 2024 Via InvestorPlace Decoding 9 Analyst Evaluations For Genmab April 30, 2024 Via Benzinga Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) June 03, 2024 From Genmab A/S Via Business Wire Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma June 02, 2024 From Genmab A/S Via Business Wire Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) June 01, 2024 From Genmab A/S Via Business Wire Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session May 24, 2024 Via Benzinga Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Genmab A/S Via Business Wire Genmab Completes Acquisition of ProfoundBio May 21, 2024 From Genmab A/S Via Business Wire 7 Biotech Stocks That Could Breathe New Life Into Your Portfolio May 20, 2024 Via InvestorPlace Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress May 14, 2024 From Genmab A/S Via Business Wire GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Genmab A/S Via Business Wire FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Pfizer Inc. Via Business Wire Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market April 25, 2024 Via Investor's Business Daily Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
